West Oak Capital LLC Buys 59 Shares of Amgen Inc. (NASDAQ:AMGN)

West Oak Capital LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 0.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,536 shares of the medical research company’s stock after acquiring an additional 59 shares during the period. West Oak Capital LLC’s holdings in Amgen were worth $2,427,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. MV Capital Management Inc. increased its position in Amgen by 2.3% in the 1st quarter. MV Capital Management Inc. now owns 7,965 shares of the medical research company’s stock worth $2,265,000 after buying an additional 180 shares during the period. Cullinan Associates Inc. increased its position in Amgen by 12.0% in the 1st quarter. Cullinan Associates Inc. now owns 174,620 shares of the medical research company’s stock worth $49,648,000 after buying an additional 18,733 shares during the period. Tributary Capital Management LLC increased its position in Amgen by 30.7% in the 1st quarter. Tributary Capital Management LLC now owns 2,173 shares of the medical research company’s stock worth $618,000 after buying an additional 510 shares during the period. Steele Capital Management Inc. increased its position in Amgen by 24.9% in the 1st quarter. Steele Capital Management Inc. now owns 1,288 shares of the medical research company’s stock worth $366,000 after buying an additional 257 shares during the period. Finally, Silvia Mccoll Wealth Management LLC increased its position in Amgen by 13.1% in the 1st quarter. Silvia Mccoll Wealth Management LLC now owns 3,652 shares of the medical research company’s stock worth $973,000 after buying an additional 423 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 0.1 %

Shares of AMGN traded down $0.24 during trading hours on Tuesday, hitting $310.77. 1,542,747 shares of the stock traded hands, compared to its average volume of 2,773,284. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 1-year low of $218.44 and a 1-year high of $329.72. The firm has a market capitalization of $166.71 billion, a PE ratio of 44.47, a price-to-earnings-growth ratio of 2.82 and a beta of 0.58. The business has a fifty day moving average of $302.34 and a 200-day moving average of $292.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm’s revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.98 earnings per share. Analysts expect that Amgen Inc. will post 19.47 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMGN shares. Mizuho boosted their price objective on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Raymond James started coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. BMO Capital Markets boosted their price objective on Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Truist Financial restated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Finally, UBS Group boosted their price target on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $307.35.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares in the company, valued at $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.